Cardiovascular diseases associated with myocardial infarction are among the major causes
of death worldwide due to the limited regenerative capacity of cardiac tissues. Although
various approaches, such as biosynthetic biomaterials, have been developed to promote
postinfarction cardiac regeneration, a number of limitations, including the immune
complications caused by biodegradation of these scaffolds and insufficient cell migration,
need to be overcome prior to their clinical application. Hence, the development of natural …